Results 21 to 30 of about 79,208 (292)

Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis

Case Reports in Oncology, 2019
Myelofibrosis (MF) can occur due to a wide variety of causes including malignant lymphoma. We report a case of splenic marginal zone lymphoma complicated by MF mimicking primary myelofibrosis (PMF).
Miyuki Tsutsui, Hajime Yasuda, Yasunori Ota, Norio Komatsu   +3 more
doaj   +1 more source

Studies of JAK2 mutations in myeloproliferative disorders [PDF]

, 2008
Myeloproliferative disorders (MPD) are diseases characterized by clonal hematopoiesis with overprodution of mature cells from erythroid, megakaryocytic and myeloid lineages.
Li, Sai
core   +1 more source

The human myeloproliferative disorders: molecular pathogenesis and clonal heterogeneity [PDF]

, 2010
The classical myeloproliferative disorders (MPD), comprising essential thrombocythaemia (ET), polycythaemia vera (PV) and idiopathic myelofibrosis (IMF), are clonal premalignant haematopoietic neoplasms associated with activating mutations in signalling ...

core   +2 more sources

Blood cell activation as an indicator of prothrombogenesis in polycythemia vera: Case control study

Iraqi Journal of Hematology, 2019
BACKGROUND: Polycythemia vera (PV) is a chronic myeloproliferative stem cell disease usually combined with JAK2 mutation. Active JAK2 mutation directly promote platelets and granulocytes activation and indirectly initiate endothelial activation.
Ibrahim A Mahmood, Farqad B Hamdan, Waseem F Al-Tameemi   +2 more
doaj   +1 more source

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

Hepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou, Kaiwei Jia, Suyuan Wang, Zhenyang Li, Yunhui Li, Shan Lu, Yingyun Yang, Liyuan Zhang, Mu Wang, Yue Dong, Luxin Zhang, Wannian Zhang, Nan Li, Yizhi Yu, Xuetao Cao, Jin Hou   +15 more
wiley   +1 more source

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia [PDF]

, 2017
JAK2 abnormalities may serve as target for precision medicines in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In the current study we performed a screening for JAK2 mutations and translocations, analyzed the clinical outcome and ...
Marco J. Koudijs, Koudijs, Marco J., Nicolle J.M. Besselink, Jerchel, I.S. (Isabel S.), Steeghs, Elisabeth M.P., Horstmann, M.A. (Martin), Boer, Judith M., Christian Michel Zwaan, Besselink, Nicolle J.M., Boer, M.L. (Monique) den, Judith M. Boer, Aurélie Boeree, Koudijs, M.J. (Marco J.), van de Ven, Cesca, Boeree, Aurélie, Boeree, A. (Aurélie), Zwaan, Christian Michel, Hester A. de Groot-Kruseman, de Goffau-Nobel, W. (Willemieke), Boer, J.M. (Judith), den Boer, Monique L., Elisabeth M.P. Steeghs, Besselink, N. (Nicolle), Cesca van de Ven, de Groot-Kruseman, Hester A., Jerchel, Isabel S., Horstmann, Martin A., Pieters, Rob, Zwaan, C.M. (Michel), Willemieke de Goffau-Nobel, de Goffau-Nobel, Willemieke, van de Ven, C. (Cesca), Rob Pieters, de Groot-Kruseman, H.A. (Hester A.), Hoogkamer, Alex Q., Martin A. Horstmann, Monique L. den Boer, Steeghs, E.M.P. (Elisabeth M.P.), Isabel S. Jerchel, Alex Q. Hoogkamer, Hoogkamer, A.Q. (Alex Q.), Pieters, R. (Rob)   +41 more
core   +2 more sources

Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review

Hematology/Oncology and Stem Cell Therapy, 2021
Primary myelofibrosis (PMF) is a subtype of BCR-ABL1 negative myeloproliferative neoplasm. Its characteristic features include clonal myeloproliferation, dysregulation of kinase signaling pathway, abnormal release of cytokines leading to fibrosis in the ...
Farhan Khalid, Moussab Damlaj, Mohsen AlZahrani, Khadega A. Abuelgasim, Giamal Edin Gmati   +4 more
doaj   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib

, 2021
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm (MPN) that harbors the Philadelphia chromosomal translocation resulting in the uncontrolled production of mature granulocytes. Commonly, patients are diagnosed with CML during blood work for
Elrazi Awadelkarim Hamid Ali (16444596), Mohamed A. Yassin (16322749), Susanna Al-Akiki (16444599)   +2 more
core   +1 more source

A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs

Molecular & Cellular Oncology, 2021
While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder, Florian Perner, Florian H. Heidel   +2 more
doaj   +1 more source